Loading
Checkpoint Therapeutics developed cosibelimab, an anti-PD-L1 antibody approved by the FDA in December 2024 for advanced cutaneous squamous cell carcinoma, and became part of Sun Pharma in May 2025.
Checkpoint Therapeutics, a Massachusetts company founded within Fortress Biotech, developed cosibelimab (Unloxcyt), an anti-PD-L1 antibody with an intact Fc region designed to add antibody-dependent cell killing to checkpoint blockade. The FDA approved it in December 2024 for metastatic or locally advanced cutaneous squamous cell carcinoma not curable by surgery or radiation, after an earlier complete response letter over a manufacturing site. Sun Pharmaceutical Industries completed its acquisition of the company on 30 May 2025, paying USD 4.10 a share in cash plus a contingent value right worth up to USD 0.70 a share, and Checkpoint continues as a wholly owned Sun Pharma subsidiary. Company facts are from the official website, FDA approval records and Checkpoint's closing filing with the SEC.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · Merger agreement dated 9 March 2025, completed 30 May 2025: USD 4.10 per share in cash plus one contingent value right of up to USD 0.70 per share; the filing does not state a total deal value | 2025 | undisclosed | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Cosibelimab is a PD-L1 antibody approved in December 2024 for advanced cutaneous squamous cell carcinoma, offering a third immunotherapy choice.
Shares Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma, Cosibelimab, CK-301-101, Cutaneous squamous cell carcinoma.
Shares Sun Pharmaceutical Industries, Cutaneous squamous cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/